{
    "organizations": [],
    "uuid": "a6b83b42cee2c78c898be699cecf041a9a219fee",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sprint-bioscience-gets-proceeds-of/brief-sprint-bioscience-gets-proceeds-of-about-sek-37-9-mln-before-issue-costs-in-rights-issue-idUSFWN1QR089",
    "ord_in_thread": 0,
    "title": "BRIEF-Sprint Bioscience Gets Proceeds Of About SEK 37.9 Mln Before Issue Costs In Rights Issue",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 9 (Reuters) - SPRINT BIOSCIENCE AB:\n* GETS PROCEEDS OF ABOUT SEK 37.9 MILLION BEFORE ISSUE COSTS IN RIGHTS ISSUE\n* ‍UPON FULL EXERCISE OF WARRANTS, CO GETS FURTHER PROCEEDS OF BETWEEN SEK 25.2-48.8 MILLION BEFORE ISSUE COSTS DURING Q1 2019​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-09T17:23:00.000+02:00",
    "crawled": "2018-03-10T20:13:27.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "sprint",
        "bioscience",
        "ab",
        "get",
        "proceeds",
        "sek",
        "million",
        "issue",
        "cost",
        "right",
        "issue",
        "full",
        "exercise",
        "warrant",
        "co",
        "get",
        "proceeds",
        "sek",
        "million",
        "issue",
        "cost",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}